Yoshida Kimihiko, Hiwasa Takaki, Ito Masaaki, Ushigome Mitsunori, Takizawa Hirotaka, Li Shu-Yang, Zhang Bo-Shi, Iwadate Yasuo, Funahashi Kimihiko, Shimada Hideaki
Department of Surgery, School of Medicine, Toho University, Tokyo 143-8541, Japan.
Department of Gastroenterological Surgery and Clinical Oncology, Graduate School of Medicine, Toho University, Tokyo 143-8541, Japan.
Oncol Lett. 2023 Feb 10;25(3):127. doi: 10.3892/ol.2023.13713. eCollection 2023 Mar.
Jumonji domain-containing 6 (JMJD6) protein has been reported to be upregulated in different cancer cells; however, to the best of our knowledge, no report has analyzed serum anti-JMJD6 antibodies (s-JMJD6-Abs) in patients with cancer. Therefore, the present study evaluated the clinical significance of s-JMJD6-Abs in patients with colorectal cancer. Preoperative serum samples were analyzed from 167 patients with colorectal cancer who underwent radical surgery between April 2007 and May 2012. The pathological stages were as follows Stage I (n=47), stage II (n=56), stage III (n=49) and stage IV (n=15). In addition, 96 healthy participants were analyzed as controls. s-JMJD6-Abs were analyzed by amplified luminescent proximity homology assay-linked immunosorbent assay. The cutoff value of s-JMJD6-Abs for detecting colorectal cancer was calculated to be 5,720 using the receiver operating characteristic curve. The positive rate of s-JMJD6-Abs was 37% in patients with colorectal cancer (61 of 167), independent of carcinoembryonic antigen or carbohydrate antigen 19-9 and p53-Abs. Clinicopathological factors and prognosis were compared between the s-JMJD6-Abs-positive group and the s-JMJD6-Abs-negative group. The s-JMJD6-Ab-positive status was significantly associated with older age (P=0.03), but was not associated with other clinicopathological variables. Regarding recurrence-free survival, the s-JMJD6-positive status was a significant poor prognostic factor in both univariate (P=0.02) and multivariate (P<0.01) analyses. Similarly, regarding overall survival, the s-JMJD6-Abs-positive status was a significant poor prognostic factor in both univariate (P=0.03) and multivariate (P=0.01) analyses. In conclusion, preoperative s-JMJD6-Abs was positive in 37% of patients with colorectal cancer and may be considered an independent poor prognostic biomarker.
据报道，含Jumonji结构域蛋白6（JMJD6）在不同癌细胞中表达上调；然而，据我们所知，尚无关于癌症患者血清抗JMJD6抗体（s-JMJD6-Abs）的分析报告。因此，本研究评估了s-JMJD6-Abs在结直肠癌患者中的临床意义。分析了2007年4月至2012年5月期间接受根治性手术的167例结直肠癌患者的术前血清样本。病理分期如下：I期（n = 47）、II期（n = 56）、III期（n = 49）和IV期（n = 15）。此外，分析了96名健康参与者作为对照。采用放大发光邻近同源分析-联免疫吸附测定法分析s-JMJD6-Abs。使用受试者工作特征曲线计算出检测结直肠癌的s-JMJD6-Abs临界值为5720。结直肠癌患者中s-JMJD6-Abs阳性率为37%（167例中的61例），与癌胚抗原、糖类抗原19-9和p53抗体无关。比较了s-JMJD6-Abs阳性组和s-JMJD6-Abs阴性组的临床病理因素及预后。s-JMJD6-Ab阳性状态与年龄较大显著相关（P = 0.03），但与其他临床病理变量无关。关于无复发生存，s-JMJD6阳性状态在单因素分析（P = 0.02）和多因素分析（P < 0.01）中均是显著的不良预后因素。同样，关于总生存，s-JMJD6-Abs阳性状态在单因素分析（P = 0.03）和多因素分析（P = 0.01）中均是显著的不良预后因素。总之，37%的结直肠癌患者术前s-JMJD6-Abs呈阳性，其可能被视为独立的不良预后生物标志物。
